Rob Abbott – CEO, ISPOR
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
ABBOTT LABORATORIES is an American-based, global, diversified healthcare firm. Among the world’s largest and most successful corporations, ABBOTT has a presence in more than 160 countries.
Cardiovascular
Diabetes
Diagnostics
Nutrition
Neuromodulation
Pharmaceuticals
Contact:
Address: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064
Tel: (224) 667-6100
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just…
Mohamed Benali Khoudja, GM for the Francophone Africa cluster at Abbott reveals the rationale behind creating a country cluster, discusses the market for local CMOs in Algeria, and expands on…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie,…
Abbott has been in Indonesia for roughly 42 years already. Over this time, has the affiliate managed to reach a positioning similar to that of the Group globally, or is…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
In 2019 big pharma companies prioritised shareholder payouts and dividends, with the eight biggest US pharma companies topping $31 billion in stock buybacks and the same amount in dividends. Revenues…
David Crean summarises the mood at the recent J.P. Morgan Healthcare Conference 2020 in San Francisco, noting a more subdued atmosphere than previous years, with reduced attendances and no big…
The AAM’s Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple public and private actors and…
Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to expect. Pharma is unlikely to be…
Matt Eyles, president and CEO of the Association of Healthcare Insurance Providers (AHIP) outlines how the US health insurance landscape has evolved in the last ten years, counters some of…
The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health…
Carla Smith looks at the three vital components behind successful strategic alliances in US healthcare:disruption, data-driven demands and convenient care delivery. Throughout my career, to bring positive and lasting…
Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs” in the US and the steps that need to be…
Monica Weldon, CEO and president of Bridge the Gap – SYNGAP Education and Research Foundation, shares her recent experience at the US Drug Law and Regulation course in Washington, DC…
Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene…
The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and…
AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward. Discussion…
See our Cookie Privacy Policy Here
